CD63 and breast carcinoma: We plan to validate the 12-protein biomarker signature in a larger cohort of 409 patients who have received adjuvant taxane therapy for breast cancer.[46] We also recognized that there were still major plasma proteins present in the CD63 enriched total exosome preparation.